

16TH INTERNATIONAL WORKSHOP on Multiple Endocrine Neoplasia

A Focus on New Concepts and Treatment of Malignant Manifestations

# March 27-29, 2019 **Houston, Texas USA**

The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB) Floor 8, Rooms 1-8 1155 Pressler Street Houston, Texas

# Register at www.men2019.com





THE UNIVERSITY OF TEXAS **MDAnderson** Cancer Center

Making Cancer History®





**Keynote Speaker:** 2018 Nobel Laureate in **Physiology or Medicine** 

James Allison, PhD

Chair Immunology The University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for Cures



# **Focus**

In keeping with the spirit of the original MEN workshop, MEN2019 will focus on emerging topics in the genesis and therapy of malignant endocrine tumors associated with multiple endocrine neoplasia. The goal of the workshop will be to provide an outline for basic and clinical research focused on these malignant manifestations. The meeting will bring together local and international experts on multiple endocrine neoplasia to focus on these subjects.

A significiant portion of the meeting will be spent in workshops centered on emerging topics and the development of an international roadmap for future research and clinical trials.

The remainder of the meeting will be composed of large group didactic sessions. The University of Texas MD Anderson Cancer Center is a leader in the development of new therapies for cancer. Our goal is to combine the extensive local scientific and clinical talent at MD Anderson along with international experts to allow focus on emerging topics including new directions in immunotherapy, emerging concepts in the use of signaling pathway inhibitors, genetic diagnosis & therapy and new clinical advances that impact management of endocrine tumor syndromes.

A specific outcome of this conference will be a white paper summarizing the goals of this work.

#### **Educational Objectives**

After attending the conference, participants should be able to:

- Identify and utilize alternative therapies to the traditional targeted therapy for the treatment of medullary thyroid cancer that may benefit their patients (Knowledge, Competence, Performance);
- Gain an awareness of modern therapy for pancreatic neuroendocrine tumors so that the most efficacious therapy may be delivered (Knowledge, Competence, Performance, Patient Outcomes);

- Utilize options to treat symptoms of excessive hormonal secretion in patients with malignant pheochromocytoma and paraganglioma (Knowledge, Competence, Performance);
- Understand menin function and telomere biology in pancreatic neuroendocrine tumors (Knowledge);
- Appreciate the clinical trials available for patients with parathyroid cancer and enroll them appropriately (Knowledge, Competence, Performance);
- Understand basic, clinical, and translational genetics with regard to TP53 germline predisposition in ACC patients (Knowledge).

### **Educational Methods**

- Lecture/Didactic
- Poster Session
- Interactive Groups/Breakouts

# **Target Audience**

This conference should be of value to clinicians (including physicians, nurse practitioners, physician assistants and genetic counselors), researchers and trainees (students, residents, and fellows).

#### **Evaluation**

A conference evaluation link will be included in the final program. This online survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

# Accreditation/Credit Designation

#### **Physicians**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 16.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category

1 Credit™ or certificates documenting
attendance will be emailed when an individual
completes the online CME Verification process.

# Presentations – WILL BE AVAILABLE

AFTER THE CONFERENCE

All of the PowerPoint presentations will be posted online after the conference. You will receive an invitation email from Study@MD Anderson to create a username and password to log into Study. If you do not receive this instructional email by April 8, 2019, please email ambaring@mdanderson.org.



# CALL FOR ABSTRACTS

Deadline for Abstract Submission is **Wednesday**, **February 13, 2019**.

The Planning Committee invites the submission of abstracts. The goal is to provide the audience an opportunity to collaborate and stimulate discussions specifically on emerging topics in the genesis and therapy of malignant endocrine tumors associated with multiple endocrine neoplasia.

Authors may submit abstracts of completed work, work in progress, or work presented elsewhere.

# **Abstract Submission Instructions:**

Abstracts will only be accepted electronically and should be uploaded to: MEN2019@mdanderson.org

Six abstracts will be chosen for an oral presentation. The remainder of the selected abstracts will be presented in a poster session.

The deadline for receipt of abstracts is 11:59 PM CST on Wednesday, February 13. Notification of acceptance for oral and/or poster presentations will be acknowledged by e-mail by Friday, March 1, 2019.

# Abstract Formatting Instructions:

Please indicate in your abstract whether you would like to be considered for an oral presentation, a poster or both. 200 word limit. Limit abstracts to one page, type in 12-point Times New Roman font, single spaced with one-inch margins, and left justified. Organize the abstract into: Background, Methods, Results, and Conclusions. Define all abbreviations. Include the abstract title, full names, and institutional affiliations of all authors, and e-mail address of the corresponding author at the top of the abstract. Underline the name of the presenting author. Abstracts must not contain copyrighted material unless permission has been obtained by the author/publisher.

The Association for Multiple Endocrine Neoplasia Disorders (AMEND USA) will be awarding the top oral presentation with a \$500 prize. We'd like to thank them for this generous contribution to the MEN 2019 16th International Workshop.



# Conference Planning Committee

#### Robert Gagel, MD (Chair)

Professor

Endocrine Neoplasia and Hormonal Disorders MD Anderson Cancer Center

#### Elizabeth Grubbs, MD (Co-Chair)

Associate Professor Surgical Oncology MD Anderson Cancer Center

#### Daniel Halperin, MD (Co-Chair)

Assistant Professor Gastrointestinal Medical Oncology MD Anderson Cancer Center

### Steven Waguespack, MD (Co-Chair)

Professor

Endocrine Neoplasia and Hormonal Disorders MD Anderson Cancer Center

#### Allison Baring, CMP

CME Conference Planner
CME/Conference Management
MD Anderson Cancer Center

### Naifa Busaidy, MD

Associate Professor Endocrine Neoplasia and Hormonal Disorders MD Anderson Cancer Center

#### Patricia L. Dahia, MD, PhD

Professor

Department of Medicine and Hematology and Medical Oncology University of Texas Health Science Center at San Antonio San Antonio, Texas

#### Mimi Hu, MD

Professor

Endocrine Neoplasia and Hormonal Disorders MD Anderson Cancer Center

#### Camilo Jimenez, MD

Professor

Endocrine Neoplasia and Hormonal Disorders MD Anderson Cancer Center

#### Nancy Perrier, MD

Professor Surgical Oncology MD Anderson Cancer Center

### **International Committee**

#### Albert Beckers, MD, PhD

Professor of Endocrinology Chu Sart Tilman Endocrinology Liège, Belgium

#### Jérôme Bertherat, MD, PhD

Head

Center for Rare Adrenal Diseases Cochin Hospital Professor of Endocrinology Paris Descartes University Paris, France

#### Maria Luisa Brandi, MD, PhD

Professor of Endocrinology University of Florence Medical School Florence, Italy

#### Friedhelm Raue, MD

Professor of Internal Medicine / Endocrinology Medical Faculty University of Heidelberg Endocrine Practice Heidelberg, Germany

# Bruce Robinson, MD, MSc, FRACP

Honorary Professor Medicine Northern Clinical School Kolling Institute of Medical Research The University of Sydney School of Medicine Sydney, Australia

### Constantine Stratakis, MD, D(Med)Sc

Scientific Director National Institute of Child Health and Human Development National Institutes of Health Bethesda, Maryland

### Rajesh V. Thakker, FRS FMedSc

May Professor of Medicine University of Oxford Oxford, England

#### Gerlof D. Valk, MD, PhD

Professor Endocrine Oncology UMC Utrecht Utrecht, Netherlands

# **Conference Agenda**

TUESD	AY, MARCH 26	MEDULLARY THYROID CANCER				
5:30 pm Registration and Welcome Reception – Mays West Lobby		1:00	Emerging Therapies In MTC RET Inhibitor LOXO-292 Lori J. Wirth, MD			
	A Celebration of the 50th anniversary of screening for Hereditary Medullary Thyroid Cancer		<b>RET Inhibitor BLU-667</b> Mimi I. Hu, MD			
WEDNE	SDAY, MARCH 27		<b>Future Trial Development for MTC</b> Vivek Subbiah, MD			
7:00 am	Registration and Continental Breakfast	1:45	Transcriptional Targeting of OncoGene Addiction in MTC			
8:00	Welcome and Opening Remarks Elizabeth Grubbs, MD	2:05	Matthew D. Ringel, MD  Lessons Learned From TCGA and Other Large			
8:05	Welcome Peter Pisters, MD		Scale Genomics Programs Kenna Shaw, PhD			
8:10	History of World MEN Conference Robert Gagel, MD	2:30	Break/Poster Viewing			
8:15	Presentation of Lifetime Achievement Award	2:45 pm – 4:45	<ul><li>Disease Site Working Groups (choose one)</li><li>Medullary Thyroid Cancer</li></ul>			
Rajesh V. Thakker, FRS FMedSci			Parathyroid Cancer			
	TIC NEUROENDOCRINE TUMORS		Pancreatic Neuroendocrine Tumor (PNET)			
Moderator: Jeffrey E. Lee, MD			Malignant Pheo/PGL			
8:30	State of the Science in Pancreatic Neuroendocrine Tumors Daniel Halperin, MD	4:45 pm	Adjourn			
8:50	<b>Emerging Therapies and Epigenetics</b> Kate Lines, PhD	THURSDAY, MARCH 28				
9:10	Menin and Telomeres in Pancreatic Neuroendocrine Tumors Christopher M. Heaphy, PhD	7:00 am	Registration and Continental Breakfast  Breakfast Talk - Hereditary Gastrointestinal			
9:30	Observational Studies of Tumor Growth Samira Sadowski, MD		Neuroendocrine Tumors (optional, non-CME)  Sponsored by Lexicon  Arvind Dasari, MD and Boris Naraev, MD, PhD			
9:50	Perioperative Clinical Trials Matthew HG Katz, MD	8:00	Welcome and Opening Remarks			
		MALIGNANT PHEOCHROMOCYTOMA AND				
		PARAGANG	LIOMA			
10:10	Poster Preview Presentations - 3 at 5 minutes each	8:10	State of the Science in Malignant Pheochromocytoma and Paraganglioma			
10:25	Break/Poster Viewing		Roderick Clifton-Bligh, BSC (med), MBBS (hons), FRACP, PhD, FFSc (RCPA)			
11:10	Panel Discussion: Common Failures in Rare Diseases (optional, non-CME) <b>Moderator:</b> Steven Sherman, MD <b>Panelists:</b> Anne Borgman, MD; Giulio Draetta, MD, PhD; George A. Fisher, Jr., MD;	8:30	Radiopharmaceuticals, Tyrosine Kinase Inhibitors and Immunotherapy for Patients with Malignant Pheochromocytoma and Paraganglioma Camilo Jimenez, MD			
12:15	Dwight Vicks III, MBA; James C. Yao, MD Lunch (provided)- Working Lunch	8:50	Pseudohypoxia as a Therapeutic Target: Lessons from Clusters One and Two Patricia L. Dahia, MD, PhD			
· <del>-</del>	4	9:10	Epigenetic Characteristics of Paraganglioma Syndrome Type 4 Mercedes Robledo, PhD			

9:30	Enabling Replicative Immortality in
	Pheochromocytoma and Paraganglioma
	Anne-Paule Gimenez-Roquenlo, MD, PhD

9:50	Break/Poster Viewing
10:00	Plenary Session: Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for Cures James Allison, PhD
11:00	Poster Preview Presentations - 3 at 5 minutes each
11:15	Break/Poster Viewing
11:45	Lunch (provided) - Working Lunch

# PARATHYROID CANCERS

12:15 pm	Presentation of FIRMO Parathyroid Medal
12:20	<b>Genetic Syndromes of PHPT and Parathyroid Cancer</b> Maria-Luisa Brandi, MD
12:40	Genetic and Molecular Alterations in Parathyroid Cancer Andrew Arnold, MD
1:00	In Vivo Roles of CDC73: Insights From Mutant Mouse Models Rajesh V. Thakker, FRS FMedSci
1:20	The Role of Local Therapies in Parathyroid Cancer: Surgery and Radiotherapy Nancy Perrier, MD
1:40	<b>Targeted Therapies and Trials in Parathyroid Cancer</b> Naifa Busaidy, MD
2:00	Break/Poster Viewing
2:20- 4:20	Disease Site Working Groups (choose one)
	Medullary Thyroid Cancer
	Parathyroid Cancer
	Pancreatic Neuroendocrine Tumor (PNET)
	Malignant Pheo/PGL
4:30	Adjourn
6:30 pm	Dinner at Space Center Houston

# FRIDAY, MARCH 29

12:00 pm

Adjourn

7:00 am	Registration and Continental Breakfast
8:00	Welcome and Opening Remarks

# PITUITARY, ADRENAL CORTEX AND ADRENOCORTICAL TUMORS

ADRENOCOR	TICAL TUMORS			
Moderator: Steven Waguespack, MD				
8:10	Aggressive Pituitary Tumors: An Update on Pathologic Features and Genomics Gérald Raverot, MD, PhD			
8:25	What is New in Familial Isolated Pituitary Adenoma? Albert Beckers, MD, PhD			
8:40	X-LAG: An Update Constantine Stratakis, MD, DMSci			
8:55	Adrenocortical Tumors: Novel Insights into Pathogenesis of Malignant Adrenocortical Tumors Tobias Else, MD			
9:10	<b>Benign Adrenocortical Tumors</b> Jérôme Bertherat, MD, PhD			
9:25	VHL as a Paradigm for the Simultaneous Treatment of Multiple Hereditary Tumors Eric Jonasch, MD			
9:40	VHL and Pancreatic NETs: An Update Electron Kebebew, MD			
10:30	Break/Poster Viewing			
10:45	Summary of Working Groups and AMEND USA Award Presentation			

#### **MD ANDERSON FACULTY**

#### James Allison, PhD

Professor and Chair Immunology Chief Scientific Advisor ad interim Vivian L. Smith Distinguished Chair Immunology

Director

Parker Institute for Cancer Immunotherapy (PICI)

Executive Director Immunotherapy Platform Deputy Director David H. Koch Center for Applied Research of Genitourinary Cancers

#### Naifa Busaidy, MD

Associate Professor Endocrine Neoplasia and Hormonal Disorders

#### Ramonda Dadu, MD

Assistant Professor Endocrine Neoplasia and HD

#### Arvind Dasari, MD

Associate Professor Gastrointestinal Medical Oncology

#### Giulio Draetta, MD, PhD

SrVP, Discovery & Platforms Therapeutics Discovery

#### Andrew Futreal, PhD

Chair Genomic Medicine

#### Daniel Halperin, MD

Assistant Professor Gastrointestinal Medical Oncology

#### Mimi I. Hu, MD

Professor

Endocrine Neoplasia and Hormonal Disorders

#### Camilo Jimenez, MD

Professor

Endocrine Neoplasia and Hormonal Disorders

#### Eric Jonasch, MD

Professor

Genitourinary Medical Oncology

#### Matthew HG Katz, MD

Associate Professor Vice Chair - Research Surgical Oncology

#### Jeffrey E. Lee, MD

Professor and Chair Surgical Oncology

### Nancy Perrier, MD

Professor Surgical Oncology Chief Section of Surgical Endocrinology Fellowship Program Director Surgical Endocrinology Associate Medical Director Multidisciplinary Endocrine Center Kenna Shaw, PhD

Executive Director Institute for Personalized Cancer Therapy

#### Steven I. Sherman, MD

Chair

Endocrine Neoplasia and Hormonal Disorders

#### Vivek Subbiah, MD

Associate Professor Investigational Cancer Therapeutics

#### James C. Yao, MD

Professor and Chair Gastrointestinal Medical Oncology

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/ exhibitors. Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

#### Andrew Arnold, MD

Murray-Heilig Chair in Molecular Medicine Professor of Medicine and Genetics and Genome Sciences

Chief

Division of Endocrinology and Metabolism Director

Center for Molecular Oncology and Chief Academic Officer

Carole and Ray Neag Comprehensive

Cancer Center

Director

Office of Physician-Scientist Career Development

Center for Molecular Oncology UConn Health

Farmington, Connecticut

#### Albert Beckers, MD, PhD

Professor and Chief Department of Endocrinology CHU de Liège Domaine Universitaire du Sart-Tilman Liège, Belgium

#### Jérôme Bertherat, MD, PhD

Professor Hôpital Cochin Paris Descartes University Paris, France

#### Anne Borgman, MD

Vice President- Clinical Development Exelixis Alameda, California

#### Maria Luisa Brandi, MD

Professor Endocrinology University of Florence Medical School Florence, Italy

### Roderick Clifton-Bligh, BSC (med), MBBS (hons), FRACP, PhD, FFSc (RCPA)

Associate Professor Medicine, Northern Clinical School Kolling Institute of Medical Research The University of Sydney School of Medicine Sydney, Australia

#### Patricia L. Dahia, MD, PhD

Professor

Department of Medicine and Hematology and Medical Oncology

University of Texas Health Science Center at San Antonio

San Antonio, Texas

#### **Tobias Else, MD**

Assistant Professor Michigan Medicine Endocrine Oncology Rogel Cancer Center Ann Arbor, Michigan

### George A. Fisher, Jr., MD

Professor Stanford Cancer Center Stanford, California

# Anne-Paule Gimenez-Roqueplo, MD, PhD

Professor Genetics Georges Pompidou European Hospital Paris, France

## Christopher M. Heaphy, PhD

Assistant Professor Pathology and Oncology The Johns Hopkins University School of Medicine Baltimore, Maryland

#### Electron Kebebew, MD

Chief
Division of General Surgery
Harry A. Oberhelman Jr. and Mark L. Welton
Professor
Program Leader, Endocrine Oncology Program
Stanford Cancer Center
Stanford, California

#### Kate Lines, PhD

Professor

Postdoctoral Researcher University of Oxford Churchill Hospital Oxford, United Kingdom

#### Boris Naraev, MD, PhD

Lead- Neuroendocrine Oncology Program Banner MD Anderson Cancer Center Adjunct Assistant Professor Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Gilbert, Arizona

#### Gérald Raverot, MD, PhD

Professor of Universities – Hospital Practitioner Department of Endocrinology and Diabetology CHU Lyon HCL - GH East Hospital Louis Pradel Lyon, France

#### Matthew D. Ringel, MD

Ralph W. Kurtz Chair and Professor of Medicine Director Division of Endocrinology, Diabetes, and Metabolism Co-Director, Thyroid Cancer Unit The James- The Ohio State University Comprehensive Cancer Center Columbus, Ohio

#### Mercedes Robledo, PhD

Hereditary Endocrine Cancer Group, Group Leader Human Cancer Genetics Program Spanish National Cancer Research Center (CNIO) Madrid, Spain

#### Samira Sadowski, MD

Assistant Clinical Investigator Endocrine Oncology Surgical Oncology Program National Institutes of Health Bethesda, Maryland

#### Constantine Stratakis, MD, DMSci

Scientific Director National Institute of Child Health and Human Development National Institutes of Health Bethesda, Maryland

#### Rajesh V. Thakker, FRS FMedSci

May Professor of Medicine Academic Endocrine Unit University of Oxford O.C.D.E.M. Churchill Hospital Headington, Oxford

#### **Dwight Vicks III, MBA**

Volunteer Treasurer International Thyroid Oncology Group President, Vicks, Inc. Yorkville, New York

#### Lori J. Wirth, MD

Medical Director Center for Head and Neck Cancers Massachusetts General Hospital Cancer Center Boston, Massachusetts



We sincerely hope you can join us for dinner at Space Center Houston on Thursday, March 28. There will be a special presentation from Col. Jack D. Fischer who is the vice commander of the 50th Space Wing, Air Force Space Command at Schriever Air Force Base in Colorado Springs, Colorado.

Col. Fischer is a distinguished graduate of the U.S. Air Force Academy and a Massachusetts Institute of Technology Draper Fellow. He flew two combat tours in the F-15E as part of Operation Southern Watch, Operation Enduring Freedom and Operation Southern Focus. As a distinguished graduate from the U.S. Air Force Test Pilot School, he also conducted flight and weapons testing in multiple variants of the F-15 and the F-22. Fischer then served nine years as an astronaut at NASA, including a 2017 mission to the International Space Station where he logged 136 days in space with two spacewalks.

Dinner will be held in the Astronaut Gallery beginning at 6:30 pm. Dinner tickets available when you register for the conference at <a href="https://www.men2019.com">www.men2019.com</a>. Tickets are \$85/person. For more information about Space Center Houston, please visit <a href="https://spacecenter.org/">https://spacecenter.org/</a>.

# **Registration Information**

Early registration and a Welcome Reception begin at 5:30 pm on Tuesday, March 26. On-site registration will begin at 7:00 am on Wednesday, March 27 and the Welcome and Introductions will begin at 8:00 am. Advanced registration is encouraged as space and materials are limited.

The deadline for advanced registration is Friday, February 15, 2019.

#### There are three ways to register:

- 1. Online at www.mdanderson.org/conferences
- 2. Fax to: 713-794-1724
- 3. Mail to: CME/Conference Management Unit 1781

The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407

### We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and a welcome reception. Please refer to the registration form for specific information regarding fees.

#### **Refund/Cancellation Policy**

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **February 15, 2019.** No refunds will be granted after that date. The request for a registration

refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

# **Special Assistance**

Contact CME/Conference Management at 713-792-2223 or toll-free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

#### **Accommodations**

- A block of rooms has been reserved for conference attendees at the Wyndham Houston – Medical Center located at 6800 South Main Street, Houston, Texas 77030.
- Early hotel reservation is suggested and the room block cutoff date is:
  - Tuesday, March 5, 2019.
- The hotel phone number is 713-528-7744
- When you make reservations, be sure

to mention the group name: Multiple Endocrine Neoplasia 2019 room block to be assured of receiving the special meeting rate of \$165 for a single or double guest room. Please add 17% Texas state and local taxes.

#### **Additional Hotel**

The Intercontinental Houston Medical Center just opened and is offering an MD Anderson rate of \$209/night. To book at this rate online, go to https://bit.ly/2DiAEqP (link is case-sensitive). You can also call the hotel at 713.422.2779 and ask for the MD Anderson rate. It is right next door to the Wyndham Houston Medical Center and both are walking distance to the conference location.

### **Ground Transportation**

(prices are subject to change and variable depending on location of conference)

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost for \$50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Wyndham Houston Medical Center for \$27 one-way and \$54 round-trip.
   For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Wyndham Houston Medical Center for \$24 one-way and \$48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle. com.

# CONFERENCE REGISTRATION - 176700/30/120473/41

**MEN 2019:** 16th International Workshop on Multiple Endocrine Neoplasia- A Focus on New Concepts and Treatment of Malignant Manifestations — **March 27-29, 2019** 

Last Name		First			MI	Highest Degree		
Department (include unit no.)				Specialty				
Institution								
MD Anderson Employee ID No. (required for all MDACC employees): Phy				Phy	Physician			
Street					<u> </u>		. 100	110
City State/Foreign					e/Foreign Co	n Country/Zip or Mail Code		
Daytime Phone (with area c	ode)		Cell Phone (with	n area code)	Fax (with area code)			
E-mail Address (please prin	nt)		<u> </u>					
Emergency Contact				Phone (with are	a coc	le)		
Credit Card Holder Name (F	irst/L	ast)					arge the followin	
Credit Card Number					Expiration Date			
Security Code/CVV/CSV	Cred	lit Card Holder Bi	Iling Address & Z	ZIP Code				
MD Anderson Interdepar	tmer	ital Transfer (ID	T) No · *Fund G	roun 90 will not	he ac	cented		
Business Unit	unoi	Department	T/140 Tund G	Fund Group*	Fun			Fund Type
Authorized Signature RE	OI II D	ED for CDEDIT	CARD or IDT	IDT Approver	Name (First/Last) please print			
			,					,
		The Univers PO Bo	ity of Texas M x 301407, Hou or fax to 71 e check or mon	nagement — Ur D Anderson Ca Iston, TX 7723 3-794-1724 Iey order payab <b>D Anderson (</b>	ance 0-14 ole to	r Center 07 o:	r	
Registration Fee:	<u> </u>							
Postmarked befo		ebruary 15						\$600
Postmarked after	Feb	ruary 15						\$70
Students/Fellows/Re	sid	ents						\$20
Genetic Counselors.								\$200
RNs/NPs/PAs								
MD Anderson Facul	-							
MD Anderson Traine								
Will you be attending	g th	e Tuesday e	vening rece <sub>l</sub>	ption at MD	And	erson?		Yes No
Space Center Housto Roundtrip transportation i			t (evening of	March 28, 2	019	:		x \$85/persoi
Which working grou (Choose One) Final workin Medullary Thyroi PNET Parathyroid Cand	ig gro	oup composition ancer			endi	ng registrat	tion interest.	